Searchable abstracts of presentations at key conferences on calcified tissues

ba0006lb3 | (1) | ICCBH2017

Mediating effect of muscle on the relationship of physical activity trajectories and bone outcomes: The Iowa Bone Development Study

Zymbal Vera , Baptista Fatima , Letuchy Elena M. , Janz Kathleen F.

Objectives: This study analysed prospective associations between two distinct developmental trajectories of objectively-measured physical activity and late adolescent bone parameters (age 17 yr) by exploring the mediating effects of lean soft tissue (LST), a surrogate of muscle mass.Methods: In approximately 349 participants (191 girls) of the Iowa Bone Development Study, physical activity was measured by accelerometry starting at age 5 and continuing at...

ba0003oc1.6 | Phosphate metabolism, fracture repair and osteoarthritis | ECTS2014

The role of neuropeptide Y Y1 receptor signalling in fracture healing

Sousa Daniela M , McDonald Michelle M , Mikulec Kathy , Peacock Lauren , Little David G , Herzog Herbert , Lamghari Meriem , Baldock Paul A

Recent studies have demonstrated that the global or osteoblast-specific deletion of neuropeptide Y Y1 receptor (Y1R), as well as the pharmacological blockade of Y1R, leads to pronounced anabolic effects in bone metabolism. This suggests that anti-Y1R drug therapy might have clinical applications for the prevention/recovery of bone loss occurring in osteoporosis. Given the high fracture incidence in this target population, it remained...

ba0003pp60 | Bone development/growth and fracture repair | ECTS2014

Effects of treatment with different bone-resorption inhibitors on alveolar wound healing process of old acyclic female rats

de Mello Wagner Garcez , de Almeida Luciana Roberta Barreto , Crivelini Marcelo Macedo , de Castro Joao Cesar Bedran , Rita Cassia Menegati Dornelles

To evaluate the regeneration of alveolar bone after treatment with bone-resorption inhibitors in old acyclic rats that had been through a long period of low estrogen. Thirty-two female Wistar rats with 20 months old intact and ovariectomized (OVX at 4 months of age), were randomized into four groups (n=8/group): i) intact; ii) OVX/O (corn oil); iii) OVX/E2 (17β-estradiol, 400 μg) and iv) OVX/RLX (Raloxifene, 1 mg/kg per day). All treatments began ...

ba0005p317 | Osteoporosis: evaluation and imaging | ECTS2016

Cellular and extracellular investigations of healing parameters in a sheep model of osteoporosis

Schaefer Annemarie , Rosch Sebastian , Weisweiler David , Boecker Wolfgang , Lips Katrin S , Heiss Christian , Malhan Deeksha , Khassawna Thaqif El

Due to its huge socio-economic impact a better understating of osteoporotic fracture healing is crucial.Thirty-one female merino land sheep were randomly divided into four groups. (i) Untreated control-group (C, n=8); (ii) bilateral ovariectomy (OVX, n=7); (iii) OVX and calcium-deficient diet (OVXD, n=8); and (iv) OVXD and additional biweekly corticosteroid injections (OVXDS, n=8). Drill-hole defects (7.5 mm in diamete...

ba0006p134 | (1) | ICCBH2017

Improvement in spinal involvement with zoledronic acid in pediatric patients with chronic recurrent multifocal osteomyelitis: a case series

Robinson Marie-Eve , Sbrocchi Anne Marie , Scuccimarri Rosie

Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare inflammatory bone disease characterized by chronic non-infectious osteomyelitis. Spinal involvement has been reported in up to 26% of patients (1). Three studies evaluated the effect of Pamidronate (PAM) on spinal lesions in pediatric patients with CRMO (1, 2, 3) and showed partial or complete resolution of vertebral hyperintensities on MRI (1). However, the effect of Zoledronic acid (ZOL) in pediatric pat...

ba0007p145 | (1) | ICCBH2019

Nine-month follow-up data on biochemical, clinical, radiological and functional parameters in a clinical cohort of children at Evelina London Children's Hospital with X-linked hypophosphataemia treated with Burosumab

Sandy Jessica L , Gilbey-Cross Robyn , Santos Rui , Sakka Sophia D , Cocca Alessandra , Morris Mavali , Cheung Moira S

Burosumab, a monoclonal antibody targeting fibroblast growth factor 23, is now available for clinical use in children with X-linked hypophosphatemia (XLH). We aimed to explore the effects of burosumab in children with XLH in a clinical setting, considering: a) Biochemistry b) Growth c) Lower limb deformity (LLD) d) Radiology e) Motor function<p class="abstext"...

ba0001pp162 | Cancer and bone: basic, translational and clinical | ECTS2013

Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer: the ZOTECT Study

Hadji Peyman , Ziller May , Maurer Tobias , Autenrieth Michael , Muth Mathias , Ruebel Amelie , May Christoph , Birkholz Katrin , Diebel Erhardt , Gleissneer Jochen , Rothe Peter , Gschwend Juergen E

Introduction: The prospective, single-arm, open-label ZOTECT study was designed to assess the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients with bone metastases.Methods: Patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) who have not received bisphosphonates for ≥6 months were enrolled at 98 sites in Ge...

ba0003oc6.3 | Osteoporosis treatment and the effects of physical activity | ECTS2014

Vitamin D is low in obesity, and this is due to greater volume of distribution

Walsh Jennifer S , Evans Amy L , Bowles Simon , Naylor Kim E , Gossiel Fatma , Jacques Richard , Schoenmakers Inez , Jones Kerry S , Eastell Richard

Low circulating levels of total 25-hydroxyvitamin D (25OHD) have been reported in obese people of different ethnicities in several countries. Low total 25OHD in obesity could be due to lower binding proteins (with normal free 25OHD), lower dietary intake or sunlight exposure, greater volume of distribution (pool size) or more rapid metabolic clearance.The aims of this study were to determine if free 25OHD and 1,25-dihydroxyvitamin D (1,25(OH)2...

ba0004p143 | (1) | ICCBH2015

Low serum vitamin D levels in children treated for hematologic oncologic diseases

Sperl Daniela , Krause Tobias , Lackner Herwig , Obermayer-Pietsch Barbara , Decrinis Clare , Berger Astrid , Sovinz Petra , Seidel Markus , Schwinger Wolfgang , Benesch Martin , Strenger Volker , Schmidt Sandrin , Urban Christian E

Objectives: Vitamin D deficiency is of current interest especially in high risk patients for reduced bone mineral density as in pediatric hematologic oncologic patients.Methods: During a 4 year period 194 pediatric hematologic oncologic patients were screened for serological vitamin D deficiency (defined as 25 (OH)D levels <30 ng/ml and accordingly <75 nmol/l). 61 patients were in the prospective group 1 defined as screening at time of diagnosis,...